Horizon scan of the clinical development landscape of biosimilar products in the UK and EU. [PDF]
Int J Technol Assess Health CareHussain A, Fairbairn R, Khan SK.
europepmc +1 more source
Sandoz Inc. v. Amgen Inc.: Removing Barriers to Market Access for Biosimilar Manufacturers [PDF]
, 2019 Koya, Moyosore O.
core +1 more source
Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap (XM17), Comparability with Gonal-f, and Performance/Consistency [PDF]
, 2017 core +1 more source
Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. [PDF]
BiologicsRanbhor R, Kulkarni P.
europepmc +1 more source
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]
Pharmaceuticals (Basel)Ponamarev VS.
europepmc +1 more source
Changes In The Prices Of Reference Biotechnology Products By The Penetration Of Biosimilars Into The Turkish Pharmaceutical Market [PDF]
Value in Health, 2015 Tuna, E, Kockaya, G
openaire +1 more source
Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars. [PDF]
World J GastroenterolMoura CS +10 more
europepmc +1 more source
Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. [PDF]
BioDrugsCar E +5 more
europepmc +1 more source
Key Regulatory Considerations for the Development of Biosimilar Pharmaceutical Products
IOSR Journal of Pharmacy (IOSRPHR), 2014 openaire +1 more source
Correction: Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial. [PDF]
Cardiovasc Diabetol Endocrinol RepGhosh S +9 more
europepmc +1 more source